WallStreetZenWallStreetZen

NASDAQ: VERU
Veru Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VERU

Based on 2 analysts offering 12 month price targets for Veru Inc

Min Forecast
$24.00+713.56%
Avg Forecast
$24.50+730.51%
Max Forecast
$25.00+747.46%

Should I buy or sell VERU stock?

Based on 2 analysts offering ratings for Veru Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VERU stock forecasts and price targets.

VERU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-04
lockedlocked$00.00+00.00%2026-05-15

1 of 1

Forecast return on equity

Is VERU forecast to generate an efficient return?

Company
-35.77%
Industry
94.37%
Market
175.99%
VERU's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VERU forecast to generate an efficient return on assets?

Company
-28.88%
Industry
27.62%
VERU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VERU earnings per share forecast

What is VERU's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.04
Avg 2 year Forecast
-$1.00
Avg 3 year Forecast
-$0.67

VERU revenue forecast

What is VERU's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

VERU vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERU$2.95$24.50+730.51%Strong Buy
MREO$0.31$1.50+385.44%Buy
MGX$1.20$9.00+650.00%Strong Buy
ACTU$2.07$15.00+624.64%Buy
ATYR$0.45$3.50+676.05%Strong Buy
View Top Biotech Stocks

Veru Stock Forecast FAQ

Is Veru Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: VERU) stock is to Strong Buy VERU stock.

Out of 2 analysts, 1 (50%) are recommending VERU as a Strong Buy, 1 (50%) are recommending VERU as a Buy, 0 (0%) are recommending VERU as a Hold, 0 (0%) are recommending VERU as a Sell, and 0 (0%) are recommending VERU as a Strong Sell.

If you're new to stock investing, here's how to buy Veru stock.

What is VERU's earnings growth forecast for 2026-2028?

(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.

Veru's earnings in 2026 is -$13,953,024.On average, 4 Wall Street analysts forecast VERU's earnings for 2026 to be -$16,616,896, with the lowest VERU earnings forecast at -$16,830,366, and the highest VERU earnings forecast at -$16,178,723. On average, 4 Wall Street analysts forecast VERU's earnings for 2027 to be -$16,125,757, with the lowest VERU earnings forecast at -$17,774,124, and the highest VERU earnings forecast at -$14,156,382.

In 2028, VERU is forecast to generate -$10,805,075 in earnings, with the lowest earnings forecast at -$13,369,917 and the highest earnings forecast at -$7,920,833.

What is VERU's revenue growth forecast for 2026-2028?

(NASDAQ: VERU) Veru's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Veru's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast VERU's revenue for 2026 to be $0, with the lowest VERU revenue forecast at $0, and the highest VERU revenue forecast at $0. On average, 4 Wall Street analysts forecast VERU's revenue for 2027 to be $0, with the lowest VERU revenue forecast at $0, and the highest VERU revenue forecast at $0.

In 2028, VERU is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is VERU's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VERU) forecast ROA is -28.88%, which is lower than the forecast US Biotechnology industry average of 27.62%.

What is VERU's Price Target?

According to 2 Wall Street analysts that have issued a 1 year VERU price target, the average VERU price target is $24.50, with the highest VERU stock price forecast at $25.00 and the lowest VERU stock price forecast at $24.00.

On average, Wall Street analysts predict that Veru's share price could reach $24.50 by Jun 4, 2027. The average Veru stock price prediction forecasts a potential upside of 730.51% from the current VERU share price of $2.95.

What is VERU's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VERU) Veru's current Earnings Per Share (EPS) is -$0.78. On average, analysts forecast that VERU's EPS will be -$1.04 for 2026, with the lowest EPS forecast at -$1.05, and the highest EPS forecast at -$1.01. On average, analysts forecast that VERU's EPS will be -$1.00 for 2027, with the lowest EPS forecast at -$1.11, and the highest EPS forecast at -$0.88. In 2028, VERU's EPS is forecast to hit -$0.67 (min: -$0.83, max: -$0.49).

What is VERU's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VERU) forecast ROE is -35.77%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.